Taegtmeyer, Anne B <br/><br/>
Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.  [electronic resource] 

 -  Swiss medical weekly  2012 
 - w13628 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1424-3997 
<br/><br/><label>Standard No.: </label>10.4414/smw.2012.13628  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aminopyridines--adverse effects<br/>Benzamides--adverse effects<br/>Cyclopropanes--adverse effects<br/>Drug Interactions<br/>Drug Therapy, Combination<br/>Humans<br/>Phosphodiesterase 4 Inhibitors--adverse effects<br/>Pulmonary Disease, Chronic Obstructive--drug therapy<br/>Severity of Illness Index